3.14. management human papillomavirus men. 3.14.1. epidemiology human papilloma virus (hpv) one frequently sexually transmitted viruses encompassing oncogenic (low- high-risk variants) non-oncogenic viruses. hpv 16 common oncogenic variant, detected 20% hpv cases . recent meta-analysis revealed prevalence 49% type hpv 35% high-risk hpv men . similar female genital tract, half hpv infections male genital tract co-infections (≥ 2 hpv strains) . hpv presence dependent study setting. men attending urological clinics hpv detected 6% urine samples . meta-analysis reported seminal hpv 4.5-15.2% patients resulting seminal hpv associated decreased male fertility . cross sectional study 430 men presenting fertility treatment detected hpv 14.9% semen samples . presence hpv semen associated impaired semen quality . however, another systematic review reported possible association hpv altered semen parameters, women possible miscarriage premature rupture membrane pregnancy . hpv6 and/or 11 common genotypes detected observational study anogenital warts, whilst hpv16 correlated severity anal cytology . incidence non-oncogenic hpv infection shown higher men women . males, approximately 33% penile cancers 90% anal cancers attributed high-risk hpv infections, primarily hpv16 . eau penial cancer guidelines publish comprehensive update march 2022 including results two systematic reviews hpv penile cancer. oral hpv associated oropharyngeal carcinomas approximately 22.4%, 4.4% 3.5% oral cavity, oropharynx larynx cancers, respectively attributed hpv . systematic reviews reported prevalence rates oral hpv 5.5-7.7%, hpv16 present 1-1.4% patients . 3.14.2. risk factors risk factors hpv infection include early age first sexual intercourse, sexual promiscuity, higher frequency sexual intercourse, smoking poor immune function [435-439]. incidence prevalence overall hpv considerably higher msm compared heterosexuals . overall, prevalence hpv different sites seems higher young, sexual-active adults compared population groups . stable sexual habits, circumcision condom use protective factors hpv [425,439-443]. added risk factors oral hpv infection alcohol consumption, poor oral hygiene sexual behaviours (oral vaginal) . positive hiv status, phimosis, hpv status partner also associated anogenital hpv status decreased clearance number studies . 3.14.3. transmission hpv typically spreads sustained direct skin-to-skin mucosal contact, vaginal, oral anal sex common transmission route . addition, hpv found surfaces medical settings public environments raising possibility object-to-skin/mucosa transmission . studies non-sexual non-penetrative sexual transmission needed understand complexity hpv transmission. hpv transmission may also influenced genotype, higher incidence hpv51 hpv52 high prevalence hpv16 hpv18 general high-risk male population . 3.14.4. clearance hpv time-to-clearance ranges 1.3 42.1 months . clearance may influenced hpv genotype, patients’ characteristics affected body site . hpv 16 highest incidence high-risk hpv variants lowest clearance across sites . 3.14.5. diagnosis currently approved test hpv men. routine testing check hpv hpv-related disease men recommended. physical examination identify hpv lesions carried out. acetic acid test diagnose sub-clinical hpv lesions may performed. diagnosis uncertain suspicion cancer biopsy carried out. intra-urethral condylomas relatively uncommon usually limited distal urethral meatus . urethrocystoscopy may used diagnose presence intra-urethral bladder warts ; however, high-level evidence use invasive diagnostic tools localisation intra-urethral hpv. detailed recommendations diagnosis anogenital warts please refer iusti‐european guideline management anogenital warts . 3.14.6. treatment hpv related diseases approximately 90% hpv infections cause problems cleared body within 2 years. however, treatment required hpv infection manifests anogenital warts prevent transmission hpv-associated anogenital infection minimise discomfort caused patients . treatment options available surgical treatment primary clearance rate approaching 100%. 3.14.6.1. treatments suitable self-application patient-applied treatments include podophyllotoxin, salicylic acid, imiquimod, polyphenon e, 5-fluoracil potassium hydroxide . imiquimod 5% cream showed total clearance external genital perianal warts 50% immunocompetent patients well hiv positive patients successfully treated highly active antiretroviral therapy . cochrane review published rcts found imiquimod superior placebo achieving complete clearance warts (rr: 4.03, 95% ci: 2.03–7.99) . recommended treatment schedule imiquimod 5% cream applied external warts overnight 3 times week 16 weeks . rct involving 502 patients genital and/or perianal warts sinecatechins 15% 10% showed complete clearance baseline newly occurring warts 57.2% 56.3% patients, respectively vs. 33.7% placebo . addition, sinecatechins 10% shown associated lower short-term recurrence rates used sequential therapy laser co2 ablative therapy . sinecatechins applied three times daily complete clearance, 16 weeks. clearance rates 36–83% podophyllotoxin solution 43–70% podophyllotoxin cream reported . systematic review meta‐analysis confirmed effectiveness podophyllotoxin 0.5% solution relative placebo (rr: 19.86, 95% ci: 3.88–101.65) . podophyllotoxin self‐applied lesions twice daily 3 days, followed four rest days, 4 5 weeks. rct also shown potassium hydroxide 5% effective, safe, low-cost treatment modality genital warts men . 3.14.6.2. physician-administered treatment 3.14.6.2 physician-administered treatment physician-administered treatments included cryotherapy (79-88% clearance rate; 25-39% recurrence rate), surgical treatment (61-94% clearance rate), including excision, electrosurgery, electrocautery laser therapy (75% clearance rate) . physician-administered therapies associated close 100% clearance rates, also associated high rates recurrence often fail eliminate invisible hpv-infected lesions . data superiority one treatment another available. however, among interventions evaluated recent systematic review network meta-analysis, surgical excision appeared effective treatment minimising risk recurrence . 3.14.6.3. summary evidence recommendations treatment anogenital warts summary evidencelea cochrane review published rcts found imiquimod superior placebo achieving complete clearance warts.1bin rct sinecatechins 15% 10% showed complete clearance baseline newly occurring warts 57.2% 56.3% patients, respectively vs. 33.7% placebo1ba systematic review meta‐analysis confirmed effectiveness podophyllotoxin 0.5% solution relative placebo1ba systematic review meta-analysis reported among physician-applied therapy, surgical excision seemed effective minimising risk recurrence.1a recommendationsstrength ratinguse self-administered imiquimod 5% cream applied external warts overnight 3 times week 16 weeks treatment anogenital warts.stronguse self-administered sinecatechins 15% 10% applied external warts three times daily complete clearance, 16 weeks treatment anogenital warts.stronguse self-administered podophyllotoxin 0.5% self‐applied lesions twice daily 3 days, followed four rest days, 4 5 weeks treatment anogenital warts.stronguse cryotherapy surgical treatment (excision, electrosurgery, electrocautery laser therapy) treat anogenital warts based informed discussion patient.strong 3.14.7. circumcision reduction hpv prevalence male circumcision simple surgical procedure shown reduce incidence sexually transmitted infections including hiv, syphilis hsv-2 . two systematic reviews meta-analyses, showed inverse association male circumcision genital hpv prevalence men . suggested male circumcision could considered additional one-time preventative intervention likely reduce burden hpv-related diseases men women, particularly among countries hpv vaccination programs cervical screening available . summary evidenceletwo systematic reviews meta-analyses, showed inverse association male circumcision genital hpv prevalence men1a recommendationstrength ratingdiscuss male circumcision patients additional one-time preventative intervention hpv-related diseases.strong 3.14.8. therapeutic vaccination three different vaccines hpv licensed date, routine vaccination males currently implemented countries including australia, canada, usa austria16. aim male vaccination reduce rate anal penile cancers well head neck cancers . systematic review including total 5,294 patients reported vaccine efficacy persisting (at least six months) anogenital hpv16 infections 46.9% (28.6-60.8%) persisting oral infections 88% (2–98%). vaccine efficacy 61.9% (21.4–82.8%) 46.8% (20-77.9%) observed anal intraepithelial neoplasia grade 2 3 lesions, respectively . systematic review reported meaningful estimates vaccine efficacy penile intraepithelial neoplasia grade 2 3, data identified anal, penile head neck squamous cell cancers . phase iii clinical trial including 180 male patients evaluated potential mva e2 recombinant vaccinia virus treat intraepithelial lesions associated papillomavirus infection . study showed promising results terms immune system stimulation hpv lesions well regression intraepithelial lesions. summary evidencelethe role therapeutic hpv vaccination males terms effectiveness safety limited small number relevant studies.2therapeutic hpv vaccination males moderately effective persistent anogenital hpv16 infection [(46.9% (28.6-60.8%)] high-grade anal intraepithelial lesions [grade 2: 61.9% (21.4–82.8%); grade 3: 46.8% (20-77.9%)].1b recommendationstrength ratingoffer hpv vaccine males surgical removal high-grade anal intraepithelial neoplasia.weak 3.14.9. prophylactic vaccination systematic review meta-analysis reported vaccination moderately effective genital hpv-related diseases irrespective individual’s hpv status; however, higher vaccine efficacy observed hpv-naïve males . supporting early vaccination boys goal establishing optimal vaccine-induced protection onset sexual activity . rct including 1,124 demonstrated high efficacy quadrivalent hpv vaccine vs. placebo hpv6/11/16/18-related persistent infections . furthermore, vaccine elicited robust immune response well tolerated mild vaccination-related adverse events e.g. injection-site pain swelling . addition, cochrane review, demonstrated quadrivalent hpv vaccine appears effective prevention external genital lesions genital warts males . despite fact quadrivalent hpv vaccines approved use young adult males 2010 vaccination rates remained low 10-15% . barriers uptake patient group include lack awareness hpv vaccines hpv-related diseases, concerns vaccine safety efficacy, economic/cost issues related vaccine uptake, underestimation hpv infection risks sexual activity . health care professionals provide easily understood accessible communication resources regarding issues, order educate young adult males families importance hpv vaccination reduce incidence certain cancers later life . summary evidencelehpv vaccine effective prevention external genital lesions genital warts males.1ahpv vaccination moderately effective genital hpv-related diseases irrespective individual’s hpv status; however, higher vaccine efficacy observed hpv-naïve males.1aa systematic review hpv vaccination barriers among adolescent young adult males identified number barriers vaccine uptake including fear side-effects, limited hpv awareness, financial costs changes sexual activity.1ban intervention study evaluate whether electronic messaging increase human papillomavirus vaccine completion knowledge among college students concluded intervention increased knowledge vaccine completion.2b recommendationsstrength ratingoffer early hpv vaccination boys goal establishing optimal vaccine-induced protection onset sexual activity.strongapply diverse communication strategies order improve hpv vaccination knowledge young adult males.strong figure 3: diagnostic treatment algorithm management hpv men